In the third edition of our “Meet the Team” blog series, we talk to Peter Ngum, one of Combinostics’ Clinical Application Specialists, about his academic and industry experience, what he loves about his role, and some fascinating conferences he’s attended recently.
Although detection of and differentiation among the various types of dementia remain challenging for clinicians, technological advances such as artificial intelligence (AI) and machine learning (ML) can help.
The theme of RSNA 2021 was “Redefining Radiology,” and, according to our CEO Richard Hausmann, the event delivered. Read Richard's 5 takeaways, from the potential of AI for radiology to the importance of data for patient care.
In our second post of the “Meet the Team” series, we sat down with Combinostics Imaging Scientist Jin Gong, to chat about her degrees, her personal connection with Alzheimer’s disease (AD), and her love of travel, gaming, and great bargains.
Drug development and selection of drugs for patients in clinical practice for Alzheimer's disease are challenged by many factors, including patient heterogeneity. AI had the potential to help select patients for whom a drug is most suitable — in trials and in practice.
In this first post of our “Meet the Team” blog series, we talked to Richard Hausmann, CEO of Combinostics, about his background, interests, and love for vintage Volkswagens.
Combinostics US Inc.
177 Huntington Ave
17th Floor
Boston, MA 02115, USA
© Combinostics | Privacy Policy
